Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | ADA | P00813 | 1/20 | 0.48 |
| ▸ | AHCY | P23526 | 3/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.44 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.44 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.44 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.44 |
| ▸ | LDHA | P00338 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | FBP1 | P09467 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.44 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.44 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.44 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9561146 | 0.85 | DNMT3B (0.58) | DNMT3BKDM4EPKMADAADORA1 | |
| SCHEMBL999366 | 0.85 | DNMT3B (0.56) | DNMT3BKDM4EPKMADAADORA1 | |
| SCHEMBL29086956 | 0.83 | DNMT3B (0.57) | DNMT3BKDM4EPKMADAADORA1 | |
| SCHEMBL29086983 | 0.83 | DNMT3B (0.57) | DNMT3BKDM4EPKMADAADORA1 | |
| SCHEMBL3821111 | 0.83 | DNMT3B (0.57) | DNMT3BKDM4EPKMADAADORA1 | |
| Nebularine SCHEMBL742475 | 0.82 | ADA (0.65) | DNMT3BKDM4EPKMADAADORA1 | |
| Nebularine SCHEMBL745560 | 0.82 | ADA (0.65) | DNMT3BKDM4EPKMADAADORA1 | |
| Nebularine SCHEMBL10666450 | 0.82 | ADA (0.65) | DNMT3BKDM4EPKMADAADORA1 | |
| Nebularine SCHEMBL9644429 | 0.82 | ADA (0.65) | DNMT3BKDM4EPKMADAADORA1 | |
| Nebularine SCHEMBL29362246 | 0.82 | ADA (0.65) | DNMT3BKDM4EPKMADAADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1491201-B1 | Methods of reducing toxicity of 5-fluorouracil with acylated pyrimidine nucleosides | WELLSTAT THERAPEUTICS CORP (US) | 2006-03-22 | — | — | EP | claimed |
| EP-0831849-A4 | METHODS OF REDUCING TOXICITY OF CHEMOTHERAPEUTIC AND ANTIVIRAL AGENTS WITH ACYLATED PYRIMIDINE NUCLEOSIDES | WELLSTAT THERAPEUTICS CORP (US) | 2003-03-26 | — | — | EP | claimed |
| US-6344447-B2 | ADMINISTERING MIXTURE OF NUCLEOSIDES; ANTICANCER AGENT | PRO-NEURON, INC. | 2002-02-05 | — | — | US | claimed |
| US-20010025032-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | VON BORSTEL REID W (US) | 2001-09-27 | — | — | US | claimed |
| US-5968914-A | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides | PRO-NEURON, INC. (US) | 1999-10-19 | — | — | US | claimed |
| EP-0831855-A1 | NUCLEOTIDE ANALOGUES FOR TOPICAL TREATMENT OF PROLIFERATIVE DISEASE OF THE SKIN | HOSTETLER, Karl Y. (US) | 1998-04-01 | — | — | EP | claimed |
| EP-0831849-A1 | METHODS OF REDUCING TOXICITY OF CHEMOTHERAPEUTIC AND ANTIVIRAL AGENTS WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1998-04-01 | — | — | EP | claimed |
| WO-1996040165-A1 | METHODS OF REDUCING TOXICITY OF CHEMOTHERAPEUTIC AND ANTIVIRAL AGENTS WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1996040166-A1 | NUCLEOTIDE ANALOGUES FOR TOPICAL TREATMENT OF PROLIFERATIVE DISEASE OF THE SKIN | HOSTETLER KARL Y (US) | 1996-12-19 | — | — | WO | claimed |
| WO-2024144987-A1 | SKIN PERFECTING AND TIGHTENING COMPOSITIONS | L'OREAL (FR) | 2024-07-04 | — | — | WO | disclosed |
| US-20100069319-A1 | Mercaptopurine derivatives and uses thereof | MIRON, TALIA (IL) | 2010-03-18 | — | — | US | disclosed |
| EP-2118107-A1 | MERCAPTOPURINE DERIVATIVES AS ANTICANCER AGENTS | Miron, Talia (IL) | 2009-11-18 | — | — | EP | disclosed |
| EP-1507555-A4 | INDUCTION OF ANTIGEN SPECIFIC IMMUNOLOGIC TOLERANCE | LOS ANGELES BIOMED RES INST (US) | 2009-07-15 | — | — | EP | disclosed |
| WO-2008107873-A1 | MERCAPTOPURINE DERIVATIVES AS ANTICANCER AGENTS | YEDA RES & DEV (IL) | 2008-09-12 | — | — | WO | disclosed |
| EP-0831849-A4 | METHODS OF REDUCING TOXICITY OF CHEMOTHERAPEUTIC AND ANTIVIRAL AGENTS WITH ACYLATED PYRIMIDINE NUCLEOSIDES | WELLSTAT THERAPEUTICS CORP (US) | 2003-03-26 | — | — | EP | disclosed |
| US-6344447-B2 | ADMINISTERING MIXTURE OF NUCLEOSIDES; ANTICANCER AGENT | PRO-NEURON, INC. | 2002-02-05 | — | — | US | disclosed |
| US-20010025032-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | VON BORSTEL REID W (US) | 2001-09-27 | — | — | US | disclosed |
| US-5968914-A | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides | PRO-NEURON, INC. (US) | 1999-10-19 | — | — | US | disclosed |
| EP-0831849-A1 | METHODS OF REDUCING TOXICITY OF CHEMOTHERAPEUTIC AND ANTIVIRAL AGENTS WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996040165-A1 | METHODS OF REDUCING TOXICITY OF CHEMOTHERAPEUTIC AND ANTIVIRAL AGENTS WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069319-A1 | Mercaptopurine derivatives and uses thereof | TPMT, MTAP, ENTPD5 | DNMT3B 705/4885KDM4E 1788/4885PKM 4079/4885 |
| US-20010025032-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | TYMP, NUDT1, UNG | DNMT3B 175/4885KDM4E 1056/4885PKM 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.